SHORT-TERM OUTCOMES AFTER INTERIM TREATMENT WITH BROLUCIZUMAB
- 17 January 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Retina
- Vol. 42 (5) , 899-905
Abstract
Purpose: To examine outcomes of eyes with neovascular age-related macular degeneration that were switched to brolucizumab because of an unsatisfactory response to bevacizumab, ranibizumab, and/or aflibercept and then switched back because of the presence or risk of intraocular inflammation. Methods: Retrospective case series of 51 eyes. Visual acuity and retinal anatomy on optical coherence tomography were recorded at the first brolucizumab injection (T1), the final brolucizumab injection (T2), and 6 months following the final brolucizumab injection (T3). Results: At T2, 41 eyes (41/51%, 80%) had decreased subretinal fluid (31 eyes), intraretinal fluid (12 eyes), or pigment epithelial detachment height (12 eyes). At T3, decreased subretinal fluid was sustained in 17 eyes (17/31%, 55%), decreased intraretinal fluid was sustained in eight eyes (8/12%, 67%), and decreased pigment epithelial detachment height was sustained in eight eyes (8/12%, 67%). Mean logarithm of the minimum angle of resolution visual acuity at T1, T2, and T3 was 0.396 (∼20/50), 0.441 (∼20/55), and 0.468 (∼20/59), respectively. During the brolucizumab treatment period, 11 eyes (11/51%, 22%) developed intraocular inflammation, including one case of retinal vasculitis. Conclusion: Interim treatment with brolucizumab resulted in anatomical improvements in 41 eyes (41/51%, 80%) that were maintained in 22 of these eyes (22/41%, 54%) for at least 6 months after switching back to the original anti–vascular endothelial growth factor therapeutic. There were no corresponding significant changes in visual acuity.Keywords
This publication has 18 references indexed in Scilit:
- Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend RegimenOphthalmology, 2019
- Evaluating Effects of Switching Anti–Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular EdemaJAMA Ophthalmology, 2017
- IMPLICATION OF RECURRENT OR RETAINED FLUID ON OPTICAL COHERENCE TOMOGRAPHY FOR VISUAL ACUITY DURING ACTIVE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH A TREAT AND EXTEND PROTOCOLRetina, 2016
- SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMABRetina, 2015
- Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practiceGraefe's Archive for Clinical and Experimental Ophthalmology, 2015
- Postmarketing Analysis of Aflibercept-Related Sterile Intraocular InflammationJAMA Ophthalmology, 2015
- Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMDEye, 2014
- Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degenerationGraefe's Archive for Clinical and Experimental Ophthalmology, 2013
- Aflibercept-Related Sterile InflammationOphthalmology, 2013
- Anti-VEGF Treatment Strategies for Wet AMDJournal of Ophthalmology, 2012